# Jesper BÃ¸je Andersen

List of Publications by Year
in descending order



| 106 | 8,952 | 45 | 91 |
| --- | --- | --- | --- |
| papers | citations | h-index | g-index |
| | | 53794 | 43889 |

| 108 | 108 | 108 | 11906 |
| --- | --- | --- | --- |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The proteaseâ€inhibitor SerpinB3 as a critical modulator of the stemâ€like subset in human cholangiocarcinoma. Liver International, 2022, 42, 233-248. | 3.9 | 15 |
| 2 | Mucosalâ€associated invariant Tâ€cell tumor infiltration predicts longâ€term survival in cholangiocarcinoma. Hepatology, 2022, 75, 1154-1168. | 7.3 | 14 |
| 3 | Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics, 2022, 12, 260-276. | 10.0 | 16 |
| 4 | Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology, 2022, 76, 1617-1633. | 7.3 | 15 |
| 5 | miRâ€579â€3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3â€Kinaseâ€“Protein Kinase B Pathway in Chronically Inflamed Liver. Hepatology Communications, 2022, 6, 1467-1481. | 4.3 | 8 |
| 6 | Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121. | 3.7 | 119 |
| 7 | Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities. Advances in Cancer Research, 2022, , . | 5.0 | 1 |
| 8 | Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190. | 3.7 | 11 |
| 9 | Lipid alterations in chronic liver disease and liver cancer. JHEP Reports, 2022, 4, 100479. | 4.9 | 69 |
| 10 | Mutational signatures and processes in hepatobiliary cancers. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 367-382. | 17.8 | 2 |
| 11 | Stromal yinâ€yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma. Hepatology, 2022, , . | 7.3 | 0 |
| 12 | Involvement of Epigenomic Factors in Bile Duct Cancer. Seminars in Liver Disease, 2022, 42, 202-211. | 3.6 | 0 |
| 13 | Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. Journal of Hepatology, 2022, 77, 1047-1058. | 3.7 | 7 |
| 14 | Molecular Targets in Cholangiocarcinoma. Hepatology, 2021, 73, 62-74. | 7.3 | 26 |
| 15 | Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. Journal of Hepatology, 2021, 74, 1132-1144. | 3.7 | 30 |
| 16 | TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut, 2021, 70, 1345-1361. | 12.1 | 59 |
| 17 | E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. Cancer Research, 2021, 81, 2874-2887. | 0.9 | 27 |
| 18 | Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1373-1385. | 3.7 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Extracellular Signalâ€Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. Hepatology, 2021, 74, 2007-2020. | 7.3 | 12 |
| 20 | Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis. JCI Insight, 2021, 6, . | 5.0 | 9 |
| 21 | Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer, 2021, 21, 1079. | 2.6 | 14 |
| 22 | The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine, 2021, 73, 103661. | 6.1 | 31 |
| 23 | Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance. Haematologica, 2021, 106, 1762-1766. | 3.5 | 6 |
| 24 | Identification of a Panâ€Gammaâ€Secretase Inhibitor Response Signature for Notchâ€Driven Cholangiocarcinoma. Hepatology, 2020, 71, 196-213. | 7.3 | 29 |
| 25 | Dual-initiation promoters with intertwined canonical and TCT/TOP transcription start sites diversify transcript processing. Nature Communications, 2020, 11, 168. | 12.8 | 37 |
| 26 | Determination of primary microRNA processing in clinical samples by targeted pri-miR-sequencing. Rna, 2020, 26, 1726-1730. | 3.5 | 5 |
| 27 | Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment. Journal of Hepatology, 2020, 73, 1007-1009. | 3.7 | 9 |
| 28 | Ancestrally Duplicated Conserved Noncoding Element Suggests Dual Regulatory Roles of HOTAIR in cis and trans. IScience, 2020, 23, 101008. | 4.1 | 9 |
| 29 | Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. Clinical Cancer Research, 2020, 26, 5655-5667. | 7.0 | 21 |
| 30 | Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721. | 4.1 | 63 |
| 31 | Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma. Journal of Cancer, 2020, 11, 2241-2251. | 2.5 | 1 |
| 32 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588. | 17.8 | 1,155 |
| 33 | Epigenome Remodeling in Cholangiocarcinoma. Trends in Cancer, 2019, 5, 335-350. | 7.4 | 36 |
| 34 | The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. Oncogenesis, 2019, 8, 61. | 4.9 | 27 |
| 35 | Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma. , 2019, , 551-562. | | 0 |
| 36 | Cholangiocarcinoma: Stateâ€ofâ€theâ€art knowledge and challenges. Liver International, 2019, 39, 5-6. | 3.9 | 6 |

| # | Article | IF | Citations |
| --- | --- | --- | --- |
| 37 | Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?. Liver International, 2019, 39, 32-42. | 3.9 | 21 |
| 38 | Causes of hOCT1â€Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumorâ€Selective Gene Therapy. Hepatology, 2019, 70, 1246-1261. | 7.3 | 41 |
| 39 | A morphogenetic EphB/EphrinB code controls hepatopancreatic duct formation. Nature Communications, 2019, 10, 5220. | 12.8 | 14 |
| 40 | Metabolic rearrangements in primary liver cancers: cause and consequences. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 748-766. | 17.8 | 144 |
| 41 | Epigenetic events involved in organic cation transporter 1â€dependent impaired response of hepatocellular carcinoma to sorafenib. British Journal of Pharmacology, 2019, 176, 787-800. | 5.4 | 39 |
| 42 | Application of patientâ€derived liver cancer cells for phenotypic characterization and therapeutic target identification. International Journal of Cancer, 2019, 144, 2782-2794. | 5.1 | 19 |
| 43 | Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. Trends in Cancer, 2018, 4, 239-255. | 7.4 | 92 |
| 44 | Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology, 2018, 68, 949-963. | 7.3 | 106 |
| 45 | Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver International, 2018, 38, 113-124. | 3.9 | 33 |
| 46 | Epigenome dysregulation in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1423-1434. | 3.8 | 31 |
| 47 | Reply. Gastroenterology, 2018, 154, 260-261. | 1.3 | 0 |
| 48 | MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5. | 1.3 | 94 |
| 49 | A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily. Cell Systems, 2018, 7, 422-437.e7. | 6.2 | 134 |
| 50 | Single cell profiling reveals window for immunotherapy in liver cancers. Hepatobiliary Surgery and Nutrition, 2018, 7, 48-51. | 1.5 | 3 |
| 51 | RNAi screening of subtracted transcriptomes reveals tumor suppression by taurine-activated GABAA receptors involved in volume regulation. PLoS ONE, 2018, 13, e0196979. | 2.5 | 1 |
| 52 | An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 2017, 8, 14294. | 12.8 | 119 |
| 53 | SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. Journal of Hepatology, 2017, 67, 72-83. | 3.7 | 81 |
| 54 | Advances in the molecular characterization of liver tumors. , 2017, , 133-138.e2. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. Expert Review of Gastroenterology and Hepatology, 2017, 11, 349-356. | 3.0 | 16 |
| 56 | Association of Aflatoxin and Gallbladder Cancer. Gastroenterology, 2017, 153, 488-494.e1. | 1.3 | 49 |
| 57 | High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Molecular Carcinogenesis, 2017, 56, 2146-2157. | 2.7 | 17 |
| 58 | Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell, 2017, 32, 57-70.e3. | 16.8 | 324 |
| 59 | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794. | 6.4 | 416 |
| 60 | Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Scientific Reports, 2017, 7, 17667. | 3.3 | 60 |
| 61 | Genetic Optimization of Liver Cancer Therapy: A Patient-Derived Primary Cancer Cell-Based Model. Gastroenterology, 2017, 152, 19-21. | 1.3 | 4 |
| 62 | Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115. | 3.7 | 130 |
| 63 | Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. Oncotarget, 2017, 8, 48688-48700. | 1.8 | 15 |
| 64 | Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of Gastrointestinal Oncology, 2016, 7, 819-827. | 1.4 | 17 |
| 65 | Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. Hepatology, 2016, 63, 1888-1899. | 7.3 | 40 |
| 66 | Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280. | 17.8 | 964 |
| 67 | Transcriptional, post-transcriptional and chromatin-associated regulation of pri-miRNAs, pre-miRNAs and moRNAs. Nucleic Acids Research, 2016, 44, 3070-3081. | 14.5 | 38 |
| 68 | Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma. Digestive Diseases, 2016, 34, 440-451. | 1.9 | 20 |
| 69 | A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology, 2016, 89, 263-272. | 2.3 | 21 |
| 70 | Heterogeneity Among Liver Cancerâ€"A Hurdle to Optimizing Therapy. Gastroenterology, 2016, 150, 818-821. | 1.3 | 7 |
| 71 | Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts. Journal of Hepatology, 2015, 62, 198-207. | 3.7 | 66 |
| 72 | Fibrolamellar Hepatocellular Carcinoma: A Rare but Distinct TypeÂof Liver Cancer. Gastroenterology, 2015, 148, 707-710. | 1.3 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepatic Oncology, 2015, 2, 79-93. | 4.2 | 16 |
| 74 | Curcumin effectively inhibits oncogenic NF-ÎºB signaling and restrains stemness features in liver cancer. Journal of Hepatology, 2015, 63, 661-669. | 3.7 | 237 |
| 75 | Functional and genetic deconstruction of the cellular origin in liver cancer. Nature Reviews Cancer, 2015, 15, 653-667. | 28.4 | 249 |
| 76 | Molecular pathogenesis of intrahepatic cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 101-113. | 2.6 | 51 |
| 77 | A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepatic Oncology, 2014, 1, 143-157. | 4.2 | 16 |
| 78 | Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology, 2014, 59, 911-923. | 7.3 | 382 |
| 79 | Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. Journal of Hepatology, 2014, 60, 346-353. | 3.7 | 85 |
| 80 | Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology, 2014, 59, 2251-2262. | 7.3 | 75 |
| 81 | p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. Cell, 2014, 158, 579-592. | 28.9 | 176 |
| 82 | MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism. Cancer Research, 2014, 74, 5903-5913. | 0.9 | 71 |
| 83 | Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2. Cancer Research, 2014, 74, 4752-4761. | 0.9 | 74 |
| 84 | Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. Journal of Hepatology, 2014, 60, 855-865. | 3.7 | 262 |
| 85 | Molecular constituents of the extracellular matrix in rat liver mounting a hepatic progenitor cell response for tissue repair. Fibrogenesis and Tissue Repair, 2013, 6, 21. | 3.4 | 17 |
| 86 | Genomic Decoding of Intrahepatic Cholangiocarcinoma Reveals Therapeutic Opportunities. Gastroenterology, 2013, 144, 687-690. | 1.3 | 18 |
| 87 | Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types. Gastroenterology, 2013, 145, 221-231. | 1.3 | 153 |
| 88 | Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Genes and Development, 2013, 27, 1706-1717. | 5.9 | 90 |
| 89 | Genetic profiling of intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology, 2012, 28, 266-272. | 2.3 | 82 |
| 90 | Next-Generation Sequencing: Application in Liver Cancerâ€"Past, Present and Future?. Biology, 2012, 1, 383-394. | 2.8 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. Gastroenterology, 2012, 142, 1021-1031.e15. | 1.3 | 443 |
| 92 | Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology, 2012, 56, 1792-1803. | 7.3 | 203 |
| 93 | mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma. Science Translational Medicine, 2012, 4, 139ra84. | 12.4 | 88 |
| 94 | Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology, 2011, 54, 1031-1042. | 7.3 | 72 |
| 95 | Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. Journal of Experimental Medicine, 2011, 208, 1963-1976. | 8.5 | 183 |
| 96 | Coactivation of AKT and Î²-Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors. Cancer Research, 2011, 71, 2718-2727. | 0.9 | 73 |
| 97 | Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. Journal of Cell Biology, 2011, 194, i11-i11. | 5.2 | 0 |
| 98 | Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology, 2010, 51, 1401-1409. | 7.3 | 118 |
| 99 | An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer. Science Translational Medicine, 2010, 2, 54ra77. | 12.4 | 92 |
| 100 | Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma. Cancer Research, 2010, 70, 8264-8269. | 0.9 | 65 |
| 101 | Loss of c-Met Disrupts Gene Expression Program Required for G2/M Progression during Liver Regeneration in Mice. PLoS ONE, 2010, 5, e12739. | 2.5 | 66 |
| 102 | Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence. RNA Biology, 2009, 6, 305-315. | 3.1 | 56 |
| 103 | UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular Cancer Therapeutics, 2008, 7, 3780-3788. | 4.1 | 72 |
| 104 | Post-transcriptional Regulation of RNase-L Expression Is Mediated by the 3â€²-Untranslated Region of Its mRNA. Journal of Biological Chemistry, 2007, 282, 7950-7960. | 3.4 | 39 |
| 105 | Interaction between the 2'-5' oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. FEBS Journal, 2004, 271, 628-636. | 0.2 | 25 |
| 106 | The Altered Serum Lipidome and its Diagnostic Potential for Non-Alcoholic Fatty Liver (NAFL)-Associated Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , . | 0.4 | 1 |